Johnson & Johnson’s orthopedics sales dip in Q4: 5 notes

Johnson & Johnson on Jan. 24 posted $23.7 billion in 2022 revenue, a 4.4 percent decrease. Its orthopedic sales remained flat year-over-year, and its fourth-quarter orthopedic sales fell slightly.

Advertisement

Five things to know:

1. Orthopedic sales in the fourth quarter was $2.1 billion, a 0.4 percent decrease. Hip sales rose 1.7 percent year-over-year in the fourth quarter with $385 million, and knee sales grew 3.4 percent with $354 million.

2. Fourth quarter trauma sales fell 2.4 percent year-over-year with $710 million. The spine and sports medicine segments saw $699 million in fourth qarter sales, a 1.3 percent year-over-year decrease. 

3. Full-year orthopedic sales of $8.6 billion was the same compared to 2021 sales. 

4.  MedTech business as a whole brought in $6.8 billion on 2022, a 1.2 percent decrease from 2021.

5. Johnson & Johnson expects 2023 operational revenue to grow 3.5 percent. 

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in Orthopedic

Advertisement

Comments are closed.